Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA) Complications Measure Submission to PQM: Figures and Tables

Table of Figures

| Figure 1. THA/TKA Complications: Logic Model1 |
|---|
| Figure 2. THA/TKA Complications: Distribution of THA/TKA Risk-Standardized Complication Rates |
| (n=3,124) (CY2022/2023 Data)3 |
| Figure 3. THA/TKA Complications: Calibration Plot (A) CY2022 and (B) CY202310 |
| Figure 4. THA/TKA Complications: Calibration Plot for Patients (A) with the Dual Eligibility (DE) |
| Variable and (B) without the DE Variable (CY2022 Data)12 |
| Figure 5. THA/TKA Complications: Calibration Plot for Patients (A) with the High Area Deprivation |
| Index (ADI) Variable and (B) without the High ADI Variable (CY2022 Data)13 |
| Figure 6. THA/TKA Complications: Improvement in Hospital-level Risk-Standardized Complication |
| Rates (RSCRs) Over Time15 |
| Table of Tables |
| Table 1. THA/TKA Complications: Hospital Distribution of Risk-Standardized Complication Rates |
| (RSCRs) (CY2022/2023 Data; January 1, 2022 - December 31, 2023)2 |
| Table 2. THA/TKA Complications: Performance Scores by Decile (CY2022/2023 Data) |
| Table 3. THA/TKA Complications: Dataset Descriptions |
| Table 4. THA/TKA Complications: Accountable Entity-Level Reliability Testing Results (CY2022/2023 |
| Data) (Hospitals with >=25 Admissions)5 |
| Table 5. THA/TKA Complications: Performance Scores by Decile (CY2022/2023 Data)5 |
| Table 6. THA/TKA Complications: List of Technical Expert Panel (TEP) Members6 |
| Table 7. THA/TKA Complications: Risk-Standardized Complication Rates (RSCRs) Within Deciles of |
| Admission Volume (CY2022/2023 Data)7 |
| Table 8. THA/TKA Complications: Risk Variable Frequencies, Odds Ratios (ORs) and 95% |
| Confidence Intervals (CIs) (CY2022/2023 Data)7 |
| Table 9. THA/TKA Complications: Model Performance (Predictive Ability, C-Statistics, Overfitting) |
| (CY2022 Data)9 |
| Table 10. THA/TKA Complications: Variation in Prevalence of Social Risk Factors Across Measured |
| Entities (CY2022 Data) (Hospitals with >=25 admissions; n=1,270)11 |
| Table 11. THA/TKA Complications: Comparison of Observed Complication Rate (%) for Patients |
| with and without Social Risk Factors (CY2022 Data)11 |
| Table 12. THA/TKA Complications: Di erences in Measure Scores, and Correlation Between |
| Measure Scores, for Measure Scores Calculated with and without Social Risk Factors (Dual |
| Eligibility [DE] and High Area Deprivation Index [ADI]) (CY2022 Data)14 |
| Table 13. THA/TKA Complications: Distribution of Hospital Risk-Standardized Complication Rates |
| (RSCRs) Over Di erent Time Periods*14 |

Figure 1. THA/TKA Complications: Logic Model




Figure 1 above shows the care processes that can influence complication risk by improving healthcare management and support. Targeted efforts such as enrolling patients in peri-operative care programs, providing patient education, delivery of high-quality, and timely delivery of care for THA/TKA patients can reduce complication rates post-surgery (Navathe et al, 2017; Cyriac et al., 2016; Borza et al., 2019). A multidisciplinary team-based approach with regular monitoring of patient symptoms can be beneficial in managing complex cases, improving communication among providers, and encouraging strategies to improve healthcare support (Nag et al., 2024; Lyman et al., 2020). Hospitals have the opportunity to improve overall complication rates after a THA/TKA procedure with a focus on patient-centered approaches. This relationship between these inputs, processes and outcomes is further discussed in Section 2.2 and Section 6.2.1.

References

Borza, T., Oerline, M.K., Skolarus, T.A., Norton, E.C., Dimick, J.B., Jacobs, B.L., Herrel, L.A., Ellimoottil, C., Hollingsworth, J.M., Ryan, A.M., Miller, D.C., Shahinian, V.B., Hollenbeck, B.K., (2019). Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery. Annals of Surgery 269(5), 873-878.

https://doi.org/10.1097/sla.000000000002737

Cyriac, J., Garson, L., Schwarzkopf, R., Ahn, K., Rinehart, J., Vakharia, S., Cannesson, M., Kain, Z. (2016). Total Joint Replacement Perioperative Surgical Home Program: 2-Year Follow-Up. Anesthesia & Analgesia, 123(1), 51-62. https://doi.org/10.1213/ane.0000000000001308

Lyman, S., Hidaka, C., Fields, K., Islam, W., & Mayman, D. (2020). Monitoring patient recovery after THA or TKA using mobile technology. HSS Journal®, 16(2_suppl), 358-365.

Nag, D. S., Swain, A., Sahu, S., Sahoo, A., & Wadhwa, G. (2024). Multidisciplinary approach toward enhanced recovery after surgery for total knee arthroplasty improves outcomes. World Journal of Clinical Cases, 12(9), 1549.

Navathe, A.S., Troxel, A.B., Liao, J.M., Nan, N., Zhu, J., Zhon, W., Emanuel, E.J. (2017). Cost of Joint Replacement Using Bundled Payment Models. Journal of the American Medical Association Internal Medicine, 177(2), 214-222. https://doi.org/10.1001/jamainternmed.2016.8263

Table 1. THA/TKA Complications: Hospital Distribution of Risk-Standardized Complication Rates (RSCRs) (CY2022/2023 Data; January 1, 2022 - December 31, 2023)

| Category | January 1, 2022 - December 31, 2023 |
|-----------------------------|-------------------------------------|
| Number of Hospitals | 3,124 |
| Mean (SD) | 3.60 (0.65) |
| Range (min. – max.) | 1.47 – 8.79 |
| 10 th Percentile | 2.91 |
| 25 th Percentile | 3.27 |
| 50 th Percentile | 3.50 |
| 75 th Percentile | 3.89 |
| 90 th Percentile | 4.42 |

Figure 2. THA/TKA Complications: Distribution of THA/TKA Risk-Standardized Complication Rates (n=3,124) (CY2022/2023 Data)




Table 2. THA/TKA Complications: Performance Scores by Decile (CY2022/2023 Data)

| | Overall | Min | Decile 1 | Decile 2 | Decile 3 | Decile 4 | Decile 5 | Decile 6 | Decile 7 | Decile 8 | Decile 9 | Decile 10 | Max |
|---|---------|-------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|------|
| Mean Performance Score | 3.60 | 1.47 | 2.57 | 3.06 | 3.26 | 3.39 | 3.47 | 3.53 | 3.68 | 3.89 | 4.19 | 4.96 | 8.79 |
| N of Entities | 3,124 | 1 | 312 | 312 | 313 | 312 | 313 | 312 | 313 | 312 | 313 | 312 | 1 |
| N of Persons / Encounters / Episodes | 272,164 | 1,072 | 106,482 | 30,500 | 17,776 | 13,147 | 8,589 | 9,316 | 24,331 | 18,378 | 18,134 | 25,511 | 112 |

Table 3. THA/TKA Complications: Dataset Descriptions

| Dataset | Type of Testing | Description of Dataset |
|---|----------------------------|-------------------------------------|
| CY2022/CY2023:2-year | Reliability testing | Dates of Data: January 1, |
| Medicare Fee-for-Service (FFS) and Medicare | Validity testing | 2022-December 31, 2023 |
| Advantage (MA) dataset | Measure score distribution | Total number of hospitals |
| (January 1, 2022- | | (with at least 1 admission): |
| December 31, 2023) | Risk variable frequencies | 3,124 |
| | and odds ratios. | Total number of admissions: 272,164 |
| | | Male (n= 92,463), 33.9% |

| Dataset | Type of Testing | Description of Dataset |
|--|----------------------------|---|
| | | Female (n= 179,701), 66.0% |
| | | Dually eligible (DE) (n=23,065), 8.5% |
| | | High ADI (n= 29,094), 10.7% |
| | | Total number of hospitals with at least 25 admissions: 1,777 (57% of total) |
| | | Number of patients within facilities with at least 25 admissions: 259,441 (95%) |
| CY2022: 1-year MA+FFS | Risk variable selection | Dates of Data: January 1, |
| Dataset:1-year Medicare FFS and Medicare | Risk model performance | 2022-December 31, 2022 |
| Advantage dataset (January 1, 2022- December 31, 2022) | Social risk factor testing | Total number of hospitals (with at least 1 admission): 3,004 |
| 2000201 | | Total number of admissions: 143,526 |
| | | Total number of hospitals with at least 25 admissions: 1,775 (59% of total) |
| | | Number of patients within facilities with at least 25 admissions: 136,786 (95%) |

| Dataset | Type of Testing | Description of Dataset |
|--|-----------------------------|--|
| CY2023: 1-year MA+FFS | Validation of model testing | Dates of Data: January 1, |
| Dataset:1-year Medicare | results | 2023-December 31, 2023 |
| FFS and Medicare Advantage Dataset (January 1, 2023- December 31, 2023) | | Total number of hospitals (with at least 1 admission): 2,894 Total number of admissions: 128,638 |
| | | Total number of hospitals with at least 25 admissions: 1,766 (61% of total) Number of patients within facilities with at least 25 admissions: 122,655 (95%) |

Table 4. THA/TKA Complications: Accountable Entity-Level Reliability Testing Results (CY2022/2023 Data) (Hospitals with >=25 Admissions)

| Minimum Case Volume | Min-Max | 25 th Percentile | 50 th Percentile | 75 th Percentile |
|-------------------------------|---------------|--------------------------------|--------------------------------|-----------------------------|
| >= 1 Admission (n=3,124) | 0.046 – 0.997 | 0.324 | 0.605 | 0.813 |
| >=25 Admissions (n= 1,777) | 0.545 - 0.997 | 0.623 | 0.784 | 0.883 |

Table 5. THA/TKA Complications: Performance Scores by Decile (CY2022/2023 Data)

| | Overall | Min | Decile 1 | Decile 2 | Decile 3 | Decile 4 | Decile 5 | Decile 6 | Decile 7 | Decile 8 | Decile 9 | Decile 10 | Max |
|---|---------|-------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|--------------|-------|
| Reliability | 0.561 | 0.046 | 0.064 | 0.181 | 0.323 | 0.441 | 0.558 | 0.655 | 0.738 | 0.810 | 0.876 | 0.945 | 0.997 |
| Mean Performance Score | 3.60 | 3.57 | 3.55 | 3.59 | 3.67 | 3.63 | 3.67 | 3.75 | 3.78 | 3.69 | 3.60 | 3.08 | 2.16 |
| N of Entities | 3,124 | 149 | 265 | 380 | 270 | 330 | 324 | 310 | 307 | 311 | 315 | 312 | 1 |
| N of Persons / Encounters / Episodes | 272,164 | 149 | 381 | 1,790 | 2,713 | 5,492 | 8,621 | 12,385 | 18,237 | 28,076 | 47,621 | 146,848 | 6,172 |

Table 6. THA/TKA Complications: List of Technical Expert Panel (TEP) Members

| Name, Credentials, and Professional Role | Organizational Affiliation, City, State |
|--|---|
| Ann Borzecki, MD, MPH; Attending Physician and Research Scientist | VA Bedford Healthcare System, Bedford, VA Center for Healthcare Organization and Implementation Research, Bedford, MA |
| Sarah Brinkman, MBA, MA, CPHQ; <i>Quality Program Manager</i> | Stratis Health, Minneapolis, MN |
| Michael Duan, MS; Principal Data Scientist | Premier, Inc., Charlotte, NC |
| Richard Dutton, MD, MBA; Anesthesiologist, Adjunct Professor, Chief Quality Officer | Baylor University Medical Center Texas A&M University US Anesthesia Partners, Dallas, TX |
| Ryan Merkow, MD, MS; Surgical Oncologist, Health Services and Outcomes Researcher, Faculty Scholar | Northwestern University, Surgical Outcomes and Quality Improvement Center American College of Surgeons, Division of Research and Optimal Patient Care, Chicago, IL |
| Matthias Cheung, RPh, PhD; Adjunct Professor of Pharmacy | University of the Pacific, Thomas J. Long School of Pharmacy, Stockton, CA |
| | Eversana Life Science Services, LLC, Chicago, IL |
| Sachin Shah, MD, MPH; General Medicine and Health Administration Fellow | Massachusetts General Hospital Harvard University, Cambridge, MA |
| Lynn Stillman, RN; Program Manager Payment Innovation | Elevance Health (formerly Anthem Blue Cross/Blue Shield of New Hampshire), Bedford, NH |
| Mary Vaughan-Sarrazin, PhD; Associate Professor, Department of Internal Medicine; Director, Quantitative Unit of Health Services and Clinical Research Core, Investigator | University of Iowa Iowa City VA Medical Center, Iowa City, IA |

| Name, Credentials, and Professional Role | Organizational Affiliation, City, State |
|---|---|
| Thomas Webb , MBA, PhD candidate; <i>Associate Vice President of Quality Analytics</i> | Rush University Medical Center, Chicago, IL |
| Bonnie Weiner, MD, MSEC, MBA; Cardiologist, Professor of Medicine, Director Interventional Cardiology Research, Chief Medical Officer, Senior Medical Director | University of Massachusetts Medical School Worcester Medical Center Accreditation of Cardiovascular Excellence Avania, Harvard, MA |
| Patient | Virginia |
| Patient | Illinois |

Table 7. THA/TKA Complications: Risk-Standardized Complication Rates (RSCRs) Within Deciles of Admission Volume (CY2022/2023 Data)

| Decile | Number of Hospitals | Range of Admissions within the Decile (Min-Max) | RSCR |
|--------|---------------------|---|-------|
| 1 | 265 | 1-2 | 3.55% |
| 2 | 380 | 3-7 | 3.59% |
| 3 | 270 | 8-12 | 3.67% |
| 4 | 330 | 13-21 | 3.63% |
| 5 | 324 | 22-32 | 3.67% |
| 6 | 310 | 33-47 | 3.75% |
| 7 | 307 | 48-71 | 3.78% |
| 8 | 311 | 72-111 | 3.69% |
| 9 | 315 | 112-205 | 3.60% |
| 10 | 312 | 207-6,172 | 3.08% |

Table 8. THA/TKA Complications: Risk Variable Frequencies, Odds Ratios (ORs) and 95% Confidence Intervals (CIs) (CY2022/2023 Data)

| Variable | Description | Frequency (%) | OR (95% CI) |
|----------|---|---------------|-------------------|
| AGE | Age, mean (SD) | 75.0 (6.1) | 74.6 (6.1) |
| | ICD-10 codes during the index admission | | |
| D631 | Anemia in chronic kidney disease | 1.3 | 1.52 (1.33, 1.73) |
| D638 | Anemia in other chronic diseases classified elsewhere | 0.6 | 1.91 (1.60, 2.27) |
| E7800 | Pure hypercholesterolemia, unspecified | 13.9 | 0.87 (0.81, 0.92) |


| Variable | Description | Frequency (%) | OR (95% CI) | |
|----------|---|---------------|---------------------------------------|--|
| E8342 | Hypomagnesemia | 0.7 | 1.47 (1.22, 1.77) | |
| F0200 | Unspecified dementia without | 4.0 | 1 56 (1 34 1 82) | |
| F0390 | behavioral disturbance | 1.0 | 1.56 (1.34, 1.82) | |
| | Hypertensive heart and chronic | | | |
| | kidney disease with heart failure | | | |
| I130 | and stage 1 through stage 4 | 2.7 | 1.57 (1.43, 1.72) | |
| | chronic kidney disease, or | | | |
| | unspecified chronic kidney disease | | | |
| 1255 | Ischemic cardiomyopathy | 0.6 | 1.63 (1.38, 1.93) | |
| 12720 | Pulmonary hypertension, | 1.6 | 1.68 (1.50, 1.88) | |
| | unspecified | | , | |
| 1428 | Other cardiomyopathies | 0.6 | 1.24 (1.01, 1.52) | |
| 14820 | Chronic atrial fibrillation, | 1.5 | 1.43 (1.26, 1.63) | |
| | unspecified | | · · · | |
| 1509 | Heart failure, unspecified | 2.1 | 0.75 (0.66, 0.85) | |
| J439 | Emphysema, unspecified | 1.0 | 1.47 (1.26, 1.72) | |
| N179 | Acute kidney failure, unspecified | 2.0 | 1.55 (1.40, 1.72) | |
| Z6842 | Body mass index [BMI] 45.0-49.9, | 1.4 | 1.50 (1.30, 1.73) | |
| 200 12 | adult | | 1100 (1100; 1110) | |
| Z803 | Family history of malignant | 0.8 | 0.62 (0.46, 0.83) | |
| | neoplasm of breast | | 0.02 (0.10, 0.00) | |
| Z853 | Personal history of malignant | 4.9 | 0.96 (0.87, 1.06) | |
| | neoplasm of breast | · | (0.01) | |
| | ICD-10 codes in the 12 months | | | |
| F705 | prior to admission | 40.7 | 0.00 (0.00 0.07) | |
| E785 | Hyperlipidemia, unspecified | 49.7 | 0.93 (0.89, 0.97) | |
| F419 | Anxiety disorder, unspecified | 11.7 | 1.12 (1.05, 1.19) | |
| 110 | Essential (primary) hypertension | 75.8 | 1.12 (1.06, 1.18) | |
| L820 | Inflamed seborrheic keratosis | 7.7 | 0.88 (0.81, 0.96) | |
| M9901 | Segmental and somatic dysfunction | 3.4 | 0.84 (0.74, 0.95) | |
| | of cervical region | | , , , | |
| S0990XA | Unspecified injury of head, initial | 3.5 | 1.32 (1.21, 1.45) | |
| | encounter | | | |
| Z79891 | Long term (current) use of opiate | 3.6 | 1.22 (1.11, 1.33) | |
| | analgesic | | , , | |
| | ICD-10 codes either during the index admission or 12 months | | | |
| | | | | |
| E669 | prior to admission Obesity, unspecified | 27.2 | 1.10 (1.05, 1.16) | |
| | | | · · · · · · · · · · · · · · · · · · · | |
| E871 | Hypo-osmolality and hyponatremia | 6.9 | 1.18 (1.10, 1.26) | |
| F32A | Depression, unspecified | 16.5 | 1.28 (1.21, 1.35) | |
| I110 | Hypertensive heart disease with heart failure | 8.8 | 1.32 (1.24, 1.41) | |
| | Heart Idliule | | , | |

| Variable | Description | Frequency (%) | OR (95% CI) | |
|--------------|---|---------------|-------------------|--|
| 12510 | Atherosclerotic heart disease of native coronary artery without angina pectoris | 26.0 | 1.16 (1.10, 1.21) | |
| 1739 | Peripheral vascular disease, unspecified | 8.8 | 1.23 (1.15, 1.31) | |
| J449 | Chronic obstructive pulmonary disease, unspecified | 12.8 | 1.27 (1.21, 1.35) | |
| M1611 | Unilateral primary osteoarthritis, right hip | 25.4 | 0.93 (0.87,1.00) | |
| M1612 | Unilateral primary osteoarthritis, left hip | 21.3 | 0.93 (0.86,0.99) | |
| M1711 | Unilateral primary osteoarthritis, right knee | 45.9 | 0.98 (0.93, 1.03) | |
| M1712 | Unilateral primary osteoarthritis, left knee | 42.6 | 0.96 (0.91, 1.01) | |
| M1990 | Unspecified osteoarthritis, unspecified site | 16.2 | 1.08 (1.03, 1.14) | |
| Z6841 | Body mass index [BMI] 40.0 – 44.9, adult | 7.9 | 1.26 (1.17, 1.35) | |
| Z794 | Long term (current) use of insulin | 6.9 | 1.21 (1.12, 1.30) | |
| Z9181 | History of falling | 5.0 | 1.16 (1.07, 1.25) | |
| | Other risk variables | | | |
| MCCFI | Multiple Chronic Conditions Frailty Index | 22.8 | 1.15 (1.09, 1.20) | |
| PROC_TH A | Elective THA procedure | 36.9 | 1.79 (1.64, 1.95) | |
| TWOPRO C | Number of procedures (two vs. one) | 2.1 | 1.26 (1.08, 1.47) | |
| HX_COVID | History of COVID-19 | 15.5 | 0.98 (0.93, 1.04) | |
| MA | MA (versus FFS) | 37.4 | 1.04 (0.99, 1.08) | |

Table 9. THA/TKA Complications: Model Performance (Predictive Ability, C-Statistics, Overfitting) (CY2022 Data)

| Value | Derivation | Validation |
|--|---------------|---------------|
| Predictive Ability, % (Lowest Decile – Highest Decile) | 1.18% – 8.65% | 1.34% – 8.36% |
| C-statistic | 0.671 | 0.663 |
| Overfitting (γ0, γ1) | 0.00,1.00 | -0.240, 0.920 |

Figure 3. THA/TKA Complications: Calibration Plot (A) CY2022 and (B) CY2023 (A) CY2022



(B) CY2023




Table 10. THA/TKA Complications: Variation in Prevalence of Social Risk Factors Across Measured Entities (CY2022 Data) (Hospitals with >=25 admissions; n=1,270)


| Social Risk Factor | Median Prevalence (%) (25th Percentile) | |
|--|---|--|
| Dual Eligibility (DE) | 5.13 (2.48 – 10.00) | |
| High Area Deprivation Index (ADI) (>=85) | 6.78 (1.22 – 18.75) | |

Table 11. THA/TKA Complications: Comparison of Observed Complication Rate (%) for Patients with and without Social Risk Factors (CY2022 Data)

| Social Risk Factor | Mean Observed Mortality Rate (%) | |
|--|----------------------------------|--|
| Dual Eligibility (DE) | 4.0 | |
| Non-DE | 3.4 | |
| High Area Deprivation Index (ADI) (>=85) | 4.0 | |
| Low ADI (<85) | 3.3 | |

Figure 4. THA/TKA Complications: Calibration Plot for Patients (A) with the Dual Eligibility (DE) Variable and (B) without the DE Variable (CY2022 Data)

A) Dually Eligible Patients



B) Non-Dually Eligible Patients





Figure 5. THA/TKA Complications: Calibration Plot for Patients (A) with the High Area Deprivation Index (ADI) Variable and (B) without the High ADI Variable (CY2022 Data)

A) Patients with High ADI (>=85)



B) Patients with Low ADI (<85)




Table 12. THA/TKA Complications: Differences in Measure Scores, and Correlation Between Measure Scores, for Measure Scores Calculated with and without Social Risk Factors (Dual Eligibility [DE] and High Area Deprivation Index [ADI]) (CY2022 Data)


| Social Risk Factor | Median Difference in Measure scores (%) | IQR (25th percentile- 75th percentile) | Pearson Correlation Coefficient |
|-----------------------|--|---|------------------------------------|
| DE | 0.0000 | -0.0000 — 0.0000 | 1.000 |
| High ADI (>=85) | 0.0002 | 0.0000 - 0.0004 | 0.989 |

Table 13. THA/TKA Complications: Distribution of Hospital Risk-Standardized Complication Rates (RSCRs) Over Different Time Periods*

| | 04/2010- 03/2013 | 04/2014- 03/2017 | 04/2016- 03/2019 | 4/1/2018 – 10/2/2019 and 7/1/2020 – 3/31/2021 |
|---------------------|---------------------|---------------------|---------------------|--|
| Number of Hospitals | 3,506 | 3,459 | 3,418 | 3,445 |
| Mean (SD) | 3.3 (0.6) | 2.6 (0.5) | 2.5 (0.5) | 2.4 (0.4) |
| Range | 1.5 - 6.5 | 1.2 – 5.4 | 1.2 – 10.6 | 1.2 - 5.6 |
| 25th Percentile | 3.0 | 2.3 | 2.2 | 2.2 |
| 50th Percentile | 3.3 | 2.5 | 2.4 | 2.4 |
| 75th Percentile | 3.6 | 2.8 | 2.7 | 2.6 |

^{*}We do not include more recent data for comparison because in 2021 the measure went through a specification update that added complication codes to the outcome resulting in an increase in the outcome rate.

Figure 6. THA/TKA Complications: Improvement in Hospital-level Risk-Standardized Complication Rates (RSCRs) Over Time



Density plots showing hospital-level RSCRs for each time period studied. Each line represents a different year of data (i.e., seven 12-month periods from April 2010 to March 2011 through April 2016 to March 2017). Density plots show the estimate of an unobservable underlying probability density function and in this case can be interpreted similarly to histograms. The vertical axes display the density in percent of hospitals with a given RSCR noted on the horizontal axis; a value of 0.04 indicates an RSCR of 4%. Curves farther to the left represent higher RSCRs (or worse outcomes); curves farther to the right represent lower RSCRs (or better outcomes). Further, the wider the curve, the more variation in hospital-level complication rates after accounting for all of the comorbidities in the risk model. Therefore, the narrower the curve, the less hospital performance variation that cannot be attributed to patient-level risk factors.